MiNK Therapeutics (NASDAQ:INKT) Director Barbara Ryan Sells 1,500 Shares of Stock

MiNK Therapeutics, Inc. (NASDAQ:INKT) Director Barbara Ryan sold 1,500 shares of MiNK Therapeutics stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $12.76, for a total value of $19,140.00. Following the completion of the transaction, the director owned 21,969 shares in the company, valued at $280,324.44. The trade was a 6.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Barbara Ryan also recently made the following trade(s):

• On Tuesday, March 10th, Barbara Ryan sold 1,300 shares of MiNK Therapeutics stock. The stock was sold at an average price of $15.40, for a total value of $20,020.00.
• On Monday, March 9th, Barbara Ryan sold 200 shares of MiNK Therapeutics stock. The stock was sold at an average price of $10.17, for a total value of $2,034.00.

MiNK Therapeutics Trading Down 6.9%

NASDAQ INKT opened at $11.87 on Friday. The stock’s 50 day moving average is $11.41 and its two-hundred day moving average is $11.37. The company has a market capitalization of $59.14 million, a price-to-earnings ratio of -4.18 and a beta of 0.47. MiNK Therapeutics, Inc. has a 1-year low of $6.80 and a 1-year high of $76.00.

MiNK Therapeutics (NASDAQ:INKT) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.57) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.20. On average, analysts predict that MiNK Therapeutics, Inc. will post -2.75 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in MiNK Therapeutics stock. DRW Securities LLC acquired a new position in MiNK Therapeutics, Inc. (NASDAQ:INKT) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 25,677 shares of the company’s stock, valued at approximately $286,000. DRW Securities LLC owned about 0.55% of MiNK Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 2.87% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on INKT shares. Wall Street Zen upgraded shares of MiNK Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. HC Wainwright reiterated a “buy” rating and issued a $35.00 target price on shares of MiNK Therapeutics in a research note on Monday, May 18th. Finally, Weiss Ratings upgraded shares of MiNK Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, May 27th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $35.00.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.